CURRICULUM VITAE Robert Strohal, MD - EWMA

3/2010
• Efficacy of skin protection ointments versus skin care ointments in the metal
processing industry, acronym: SPC, prospective comparative controlled 3-phases
study at the locations Krefeld and Benrath of Thyssen-Krupp, Germany, sponsor:
Evonic-Stockhausen, Germany, start 7/08-10/09
• Reduction of itching and improvement of the skin by Cavilon ® skin protection
cream in patients with anal skin irritation/eczema (3M-CAVAE-35-08), Austrian
double-center, prospective, controlled study, sponsor: 3M Austria, 8/08-5/09
• Tolerability and antimicrobial efficacy dynamics of Octenilin ® wound gel in
critically colonized acute and chronic wounds (TAEDO-SMP-2-06/09),
prospective single center clinical pilot study, sponsor: Schülke & Mayr Global, 5/09-
10/09
� Author or Assisting Author of Compassionate Use Studies (Anwendungsbeobachtungen)
• Enbrel ® and Psoriatic Arthritis, Austrian compassionate use study by Wyeth-
Lederle Pharma, assisting author, 10/03 – 2/04
• Combination therapy of vitiligo with Vitix ® and UV-B narrow band, Austrian
compassionate use study by Sanova, originating author, 4/04-3/05
• Raptiva ® and Psoriasis, Austrian compassionate use study by Serono, assistant
author, 10/03 – 2/04
• Etanercept and conventional systemic therapies in the treatment of Psoriasis,
compassionate use study for Austria and the eastern EU countries by Wyeth-Lederle
Pharma, cooperative author of a non company-related group of authors, 10/03 – 2/04
• 5% topical Imiquimod and actinic keratoses, Austrian compassionate use study by
Meda Pharma, assisting author, 3/08-6/09
� Lead Center of International Multi-Center Clinical Studies
• A prospective pediatric longitudinal evaluation to assess the long-term safety of
Tacrolimus ointment for the treatment of atopic dermatitis (APPLES, FHI 03-0-
161/FG-506-06-37), Austrian lead center, sponsor: Astellas International, start 7/08-
• A randomized, double blind trial assessing the efficacy and safety of Etanercept
50mg twice weekly and Etanercept 50 mg once weekly for the treatment of
moderate to severe psoriasis (N° 0881A6-4425), international multi-center study,
global lead investigator together with Prof. Puig, Madrid, Spain, sponsor: Wyeth
Global, start 3/08-
� Multicenter, Company Sponsored Clinical Studies
• A 22-week randomized, multicenter, parallel-group, double-blind study to compare a
pimecrolimus 1% (Elidel) twice daily maintenance dosing regimen to a once
daily maintenance dosing regimen in the management of atopic dermatitis in
pediatric subjects, sponsor: Novartis International. 9/04 - 3/05
10